Researchers from F. Hoffmann-La Roche Ltd., Hoffmann-La Roche Inc. and Icagen Inc. have disclosed heteroaryl-urea compounds acting as potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of autism spectrum...
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified piperazinylsulfonylaryl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors.
Research at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. has led to the identification of sulfonylpiperazinyl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized GABA-A receptor γ1 subunit positive allosteric modulators (PAMs) reported to be useful for the treatment of cognitive and neurological disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented benzodiazepine derivatives acting as GABA(A) receptor subunit α2β2γ1 positive allosteric modulators and reported to be useful for the treatment of neurological disorders.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
